| Literature DB >> 29387957 |
Jeanny J A de Groot1,2, José M C Maessen3,4, Cornelis H C Dejong5,6,7, Bjorn Winkens8, Roy F P M Kruitwagen9,7, Brigitte F M Slangen9,7, Trudy van der Weijden3.
Abstract
BACKGROUND: Spread of evidence-based innovations beyond pioneering settings is essential to improve quality of care. This study aimed to evaluate the influence of a national project to implement 'Enhanced Recovery After Surgery' (ERAS) among colorectal teams on the spread of this innovation to gynaecological procedures.Entities:
Mesh:
Year: 2018 PMID: 29387957 PMCID: PMC6060819 DOI: 10.1007/s00268-018-4495-z
Source DB: PubMed Journal: World J Surg ISSN: 0364-2313 Impact factor: 3.352
ERAS elements included in retrospective analysis
| Preoperative phase | Omission of mechanical bowel preparation |
| Use of carbohydrate load | |
| Operative phase | Use of local analgesia |
| Avoidance of drains | |
| Postoperative phase | Early ambulation on the day of surgery (sitting on edge of bed) |
| Scheduled postoperative administration of laxatives | |
| Oral feeding on POD 1 | |
| Early ambulation on POD 1 (sitting on chair three times a day) | |
| Discontinuation of intravenous fluids on POD 2 | |
| Discontinuation of urinary catheter on POD 2 |
ERAS Enhanced Recovery After Surgery, POD postoperative day
Fig. 1Study flow chart
Baseline demographics of hospitals and patients according to observational group
| Control | Intervention | ||
|---|---|---|---|
| Hospital demographics | |||
| Number of hospitals | 13 | 10 | |
| Number of beds per hospitala | 642.3 ± 304.5 | 812.1 ± 189.8 | 0.138c |
| Type of hospital | 0.660d | ||
| University medical centre | 4 (30.8) | 2 (20.0) | |
| Non-university teaching hospital | 9 (69.2) | 8 (80.0) | |
| Hospital ward | |||
| Combined with colorectal surgery | 1 (7.7) | 2 (20.0) | 0.560d |
| Patient demographics | |||
| Number of patients | 390 | 294 | |
| Age, yearsa | 61.4 ± 12.0 | 62.6 ± 12.4 | 0.212c |
| Age, years | 0.016 | ||
| < 60 | 164 (42.1) | 97 (33.0) | |
| ≥ 60 | 226 (57.9) | 197 (67.0) | |
| ASA classification | 0.092 | ||
| Class I/II | 352 (90.3) | 253 (86.1) | |
| Class III/IV | 38 (9.7) | 41 (13.9) | |
| Gynaecological cancer type | 0.045 | ||
| Ovarian | 289 (74.1) | 231 (78.6) | |
| Uterine | 72 (18.5) | 54 (18.4) | |
| Cervical | 29 (7.4) | 9 (3.1) | |
| Histological subtype | 0.981 | ||
| Benign | 46 (11.8) | 36 (12.2) | |
| Borderline/hyperplasia | 30 (7.7) | 22 (7.5) | |
| Malignant | 314 (80.5) | 236 (80.3) | |
| Type of incision | 0.842 | ||
| Midline | 377 (96.7) | 285 (96.9) | |
| Transverse | 13 (3.3) | 9 (3.1) | |
Values in parentheses are percentages unless indicated otherwise
ASA American society of anaesthesiologists
aValues are mean ± standard deviation. bχ2 test, except cindependent samples t test and dFisher’s exact test
Fig. 2Model estimated marginal means in days
Fig. 3Percentage of implemented (> 70%) enhanced recovery elements among hospitals